Targeting peripherally restricted cannabinoid receptor 1, cannabinoid receptor 2, and endocannabinoid-degrading enzymes for the treatment of neuropathic pain including neuropathic orofacial pain

Mohammad Zakir Hossain*, Hiroshi Ando, Shumpei Unno, Junichi Kitagawa

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةReview articleمراجعة النظراء

32 اقتباسات (Scopus)

ملخص

Neuropathic pain conditions including neuropathic orofacial pain (NOP) are difficult to treat. Contemporary therapeutic agents for neuropathic pain are often ineffective in relieving pain and are associated with various adverse effects. Finding new options for treating neuropathic pain is a major priority in pain-related research. Cannabinoid-based therapeutic strategies have emerged as promising new options. Cannabinoids mainly act on cannabinoid 1 (CB1) and 2 (CB2) receptors, and the former is widely distributed in the brain. The therapeutic significance of cannabinoids is masked by their adverse effects including sedation, motor impairment, addiction and cognitive impairment, which are thought to be mediated by CB1 receptors in the brain. Alternative approaches have been developed to overcome this problem by selectively targeting CB2 receptors, peripherally restricted CB1 receptors and endocannabinoids that may be locally synthesized on demand at sites where their actions are pertinent. Many preclinical studies have reported that these strategies are effective for treating neuropathic pain and produce no or minimal side effects. Recently, we observed that inhibition of degradation of a major endocannabinoid, 2-arachydonoylglycerol, can attenuate NOP following trigeminal nerve injury in mice. This review will discuss the above-mentioned alternative approaches that show potential for treating neuropathic pain including NOP.

اللغة الأصليةEnglish
رقم المقال1423
دوريةInternational Journal of Molecular Sciences
مستوى الصوت21
رقم الإصدار4
المعرِّفات الرقمية للأشياء
حالة النشرPublished - فبراير 20 2020
منشور خارجيًانعم

ASJC Scopus subject areas

  • ???subjectarea.asjc.1500.1503???
  • ???subjectarea.asjc.1300.1312???
  • ???subjectarea.asjc.1600.1607???
  • ???subjectarea.asjc.1700.1706???
  • ???subjectarea.asjc.1600.1606???
  • ???subjectarea.asjc.1600.1605???
  • ???subjectarea.asjc.1600.1604???

بصمة

أدرس بدقة موضوعات البحث “Targeting peripherally restricted cannabinoid receptor 1, cannabinoid receptor 2, and endocannabinoid-degrading enzymes for the treatment of neuropathic pain including neuropathic orofacial pain'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا